SecBot SecBot
SECBOTREPLAY Home › Report › ORKA

ORKA · The company highlighted key upcoming catalysts including Week 28 data…

Oruka Therapeutics, Inc. · 8-K filed Aug 10, 2026 at 07:00 ET

At the news

NEUTRALIMPACT 5/10

8-K filed Aug 10, 2026 at 07:00 ET

The company highlighted key upcoming catalysts including Week 28 data from EVERLAST-A and Week 16 data from EVERLAST-B, while maintaining a $1.1 billion cash position expected to fund operations through a BLA filing for ORKA-001. The filing is being evaluated in the context of activist investor Fairmount Funds Management's disclosed stake from July 2026.

  • Net loss of $41.2 million for Q2 2026, compared to $24.6 million for Q2 2025
  • Cash, cash equivalents and marketable securities of $1.1 billion as of June 30, 2026
  • R&D expenses increased to $43.3 million from $24.1 million year-over-year
  • EVERLAST-B Phase 2b trial fully enrolled with 187 subjects; Week 16 data expected in Q4 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access